Using alpha particles to treat pediatric neuroblastoma
Radiation dosimetry for alpha-particle radiopharmaceutical therapy and application to pediatric neuroblastoma
['FUNDING_OTHER'] · MASSACHUSETTS GENERAL HOSPITAL · NIH-10928227
This study is looking at a new way to treat kids with neuroblastoma, a tough type of cancer, by using a special treatment that targets cancer cells directly while being gentle on healthy ones, to help improve their chances of getting better.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MASSACHUSETTS GENERAL HOSPITAL (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-10928227 on ClinicalTrials.gov |
What this research studies
This research investigates the use of alpha-particle radiopharmaceutical therapy to target and treat pediatric neuroblastoma, a challenging cancer in children. The approach involves attaching an alpha-emitting radionuclide to a ligand that specifically binds to cancer cells, allowing for precise radiation delivery while minimizing damage to healthy tissue. The study aims to rigorously determine the radiation dosimetry to optimize treatment effectiveness and safety for young patients. By focusing on the unique characteristics of alpha particles, the research seeks to improve outcomes for children with high-risk neuroblastoma.
Who could benefit from this research
Good fit: Ideal candidates for this research are children diagnosed with high-risk neuroblastoma who may benefit from targeted radiopharmaceutical therapies.
Not a fit: Patients with low-risk neuroblastoma or those who do not express the targeted biomolecules may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for children suffering from neuroblastoma.
How similar studies have performed: Previous research has shown promising results with alpha-particle therapies in treating various cancers, indicating potential success for this novel application in pediatric neuroblastoma.
Where this research is happening
BOSTON, UNITED STATES
- MASSACHUSETTS GENERAL HOSPITAL — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BERTOLET REINA, ALEJANDRO — MASSACHUSETTS GENERAL HOSPITAL
- Study coordinator: BERTOLET REINA, ALEJANDRO
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents